<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512797</url>
  </required_header>
  <id_info>
    <org_study_id>AAAO1107</org_study_id>
    <secondary_id>0000048421</secondary_id>
    <nct_id>NCT01512797</nct_id>
  </id_info>
  <brief_title>Treatment of Diabetes After Gastric Bypass With Sitagliptin</brief_title>
  <acronym>LAF33</acronym>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess Efficacy, Safety and Tolerability of Sitagliptin Phosphate 100 mg as Treatment for Recurrent, Persistent or Newly Diagnosed Type 2 Diabetes After Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blandine Laferrere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe
      and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Januvia (sitagliptin phosphate 100mg) is an FDA approved medication for the treatment of Type
      2 Diabetes. Sitagliptin works by inhibiting the Dipeptidyl peptidase-4 enzyme, resulting in
      increased active glucagon-like peptide-1 (GLP-1) levels. GLP-1 is an incretin which increases
      post-prandial insulin secretion. Because Gastric Bypass has also been shown to increase GLP-1
      levels, this study seeks to determine the additional effect of DDP-4 inhibition on glucose
      control in patients who have elevated incretin levels post Gastric Bypass. The study will
      also assess if Januvia (Sitagliptin phosphate) is safe and well tolerated in patients after
      Gastric Bypass.

      Recruitment and data collection for this study was started at St. Luke's Hospital in New
      York, NY and later moved to Columbia University Medical Center in New York, NY.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Postprandial Glucose Levels After Mixed Meal Test</measure>
    <time_frame>Baseline and ~4 weeks</time_frame>
    <description>Glucose levels were measured in study participants while fasting and periodically over 3 hours after drinking a 200 kcal mixed meal test, before and after intervention (Sitagliptin or Placebo).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Area Under the Curve (AUC) Glucose Levels After Mixed Meal Test</measure>
    <time_frame>Baseline and ~4 weeks</time_frame>
    <description>Glucose levels were measured in study participants while fasting and periodically over 3 hours after drinking a 200 kcal mixed meal test, before and after intervention (Sitagliptin or Placebo). AUC was measured by trapezoidal method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Sitagliptin vs Placebo on Satiety in Patients With Type 2 Diabetes After Gastric Bypass Surgery</measure>
    <time_frame>Baseline and ~4 weeks</time_frame>
    <description>Satiety levels were measured in study participants while they were fasting and periodically over a three hour period after drinking a 200 kcal meal drink, before and after intervention via a Visual Analog Scale. Participants were asked to mark on a 0 to 150 millimeter scale their response to the following question: &quot;How full do you feel right now?&quot; with lower scores indicating &quot;not full at all&quot; and higher scores indicating &quot;extremely full.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Side Effects In Relation to Sitagliptin</measure>
    <time_frame>6 weeks</time_frame>
    <description>Side effects to Sitagliptin or Placebo were measured in study participants via Sigstad score questionnaire, while fasting and periodically during a 3 hour period after drinking a 200 kcal meal drink, before and after intervention. The Sigstad scoring system is based on the participants report of the occurrence of 16 symptoms suggestive of the dumping syndrome. Each symptom is given a different score. For example, desire to sit down (+4), breathlessness (+3), dizziness (+2), nausea (+1), vomiting (-4) etc.The scale can range from -5 to 34. Scores greater than or equal to 7, after glucose intake, are considered diagnostic of dumping syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active GLP-1</measure>
    <time_frame>Pre-Intervention and Post-Intervention</time_frame>
    <description>Active GLP-1 (Fasting and during a Mixed Meal Test). The Change in Fasting Active GLP-1 refers to the change in fasting active GLP-1 from pre-intervention time point to post-intervention time point. The Change in Peak Active GLP-1 refers to the change in the peak active GLP-1 level from the pre-intervention time point to post-intervention time point.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin phosphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 Placebo pill / day PO once a day for 4-5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin phosphate</intervention_name>
    <description>100 mg/day orally</description>
    <arm_group_label>Sitagliptin phosphate</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 Placebo Pill per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a resident of the NYC metropolitan area or be able to come for emergency
             unscheduled and regular weekly meetings in Manhattan.

          -  HbA1c ≥ 6.5% and ≤ 8.5 % or a fasting glucose ≥ 126 mg/dL or a random glucose ≥ 200
             mg/dL at least 12 months after GBP surgery confirmed by central laboratory.

          -  Subject is capable and willing to give informed consent.

          -  Subject is otherwise in good general health, based on medical history and physical
             examination.

          -  Subject is a non smoker for at least 6 months prior to study start

          -  Female subjects of child bearing potential must use oral, injected or implanted
             hormonal methods of contraception from at least the commencement of their last normal
             period prior to the first administration of the challenge agent. Subjects using
             hormonal contraception should use a barrier method in addition from the first
             administration of challenge agent until their next normal period following the end of
             the study.

        Exclusion Criteria:

          -  History of type 1 diabetes

          -  Female subject is pregnant or breastfeeding.

          -  Recent (&lt; 30 days) or simultaneous participation in another clinical trial.

          -  Any situation that can compromise the study, including serious illness or a
             predictable lack of cooperation from the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blandine Laferrere, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Obesity Nutrition Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Obesity Nutrition Research Center, Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nyorc.org/</url>
    <description>New York Obesity Nutrition Research Center</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <results_first_submitted>December 1, 2017</results_first_submitted>
  <results_first_submitted_qc>February 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2018</results_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Blandine Laferrere</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Columbia University</investigator_title>
  </responsible_party>
  <keyword>Januvia</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Gastric-Bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for this study took place from July 2012-July 2016. Recruitment and data collection for this study was started at St. Luke's Hospital in New York, NY and later moved to Columbia University Medical Center in New York, NY.</recruitment_details>
      <pre_assignment_details>37 participants were enrolled, however only 32 participated in study procedures and demographic information collection.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin Phosphate</title>
          <description>100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Sitagliptin phosphate: 100 mg/day orally</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>1 Placebo pill / day PO once a day for 4-5 weeks
Placebo: 1 Placebo Pill per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin Phosphate</title>
          <description>100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Sitagliptin phosphate: 100 mg/day orally</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>1 Placebo pill / day PO once a day for 4-5 weeks
Placebo: 1 Placebo Pill per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="9.0"/>
                    <measurement group_id="B2" value="58.4" spread="7.0"/>
                    <measurement group_id="B3" value="56.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.70" spread="5.22"/>
                    <measurement group_id="B2" value="36.12" spread="7.69"/>
                    <measurement group_id="B3" value="34.41" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.46" spread="0.78"/>
                    <measurement group_id="B2" value="6.96" spread="0.70"/>
                    <measurement group_id="B3" value="7.21" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since Roux-en-Y gastric bypass surgery</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.56" spread="3.77"/>
                    <measurement group_id="B2" value="5.57" spread="2.80"/>
                    <measurement group_id="B3" value="5.56" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 2 Diabetes Mellitus duration prior to Roux-en-Y gastric bypass surgery</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.9" spread="11.0"/>
                    <measurement group_id="B2" value="12.9" spread="9.3"/>
                    <measurement group_id="B3" value="12.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 2 Diabetes Mellitus remission duration prior to study</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.72" spread="3.10"/>
                    <measurement group_id="B2" value="2.16" spread="2.74"/>
                    <measurement group_id="B3" value="2.44" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Weight before Roux-en-Y gastric bypass surgery</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122.45" spread="19.0"/>
                    <measurement group_id="B2" value="132.89" spread="24.23"/>
                    <measurement group_id="B3" value="127.7" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at Roux-en-Y gastric bypass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117.5" spread="20.4"/>
                    <measurement group_id="B2" value="130.23" spread="24.6"/>
                    <measurement group_id="B3" value="123.9" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nadir weight after Roux-en-Y gastric bypass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.51" spread="17.52"/>
                    <measurement group_id="B2" value="82.93" spread="13.38"/>
                    <measurement group_id="B3" value="78.22" spread="16.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.98" spread="15.21"/>
                    <measurement group_id="B2" value="95.82" spread="19.71"/>
                    <measurement group_id="B3" value="90.90" spread="18.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current weight loss since Roux-en-Y gastric bypass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.53" spread="11.90"/>
                    <measurement group_id="B2" value="34.47" spread="13.91"/>
                    <measurement group_id="B3" value="33.00" spread="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight regain from nadir weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.73" spread="10.70"/>
                    <measurement group_id="B2" value="12.96" spread="10.94"/>
                    <measurement group_id="B3" value="12.84" spread="10.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of oral type 2 diabetes mellitus medications prior to Roux-en-Y gastric bypass</title>
          <units>number of medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.88" spread="0.89"/>
                    <measurement group_id="B2" value="1.75" spread="0.93"/>
                    <measurement group_id="B3" value="1.81" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants on insulin prior to RYGB</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants on insulin at time of study</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.0" spread="41.5"/>
                    <measurement group_id="B2" value="151.78" spread="32.67"/>
                    <measurement group_id="B3" value="161.1" spread="37.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147.3" spread="123.9"/>
                    <measurement group_id="B2" value="124.7" spread="50.2"/>
                    <measurement group_id="B3" value="135.1" spread="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density lipoprotein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.83" spread="15.21"/>
                    <measurement group_id="B2" value="59.21" spread="29.39"/>
                    <measurement group_id="B3" value="57.19" spread="23.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density lipoprotein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.18" spread="39.92"/>
                    <measurement group_id="B2" value="76.79" spread="28.24"/>
                    <measurement group_id="B3" value="82.24" spread="33.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124.8" spread="21.23"/>
                    <measurement group_id="B2" value="119.1" spread="14.4"/>
                    <measurement group_id="B3" value="122.23" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.69" spread="12.26"/>
                    <measurement group_id="B2" value="69.77" spread="11.05"/>
                    <measurement group_id="B3" value="72.48" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Postprandial Glucose Levels After Mixed Meal Test</title>
        <description>Glucose levels were measured in study participants while fasting and periodically over 3 hours after drinking a 200 kcal mixed meal test, before and after intervention (Sitagliptin or Placebo).</description>
        <time_frame>Baseline and ~4 weeks</time_frame>
        <population>All patients completed study in both arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Phosphate</title>
            <description>100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Sitagliptin phosphate: 100 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 Placebo pill / day PO once a day for 4-5 weeks
Placebo: 1 Placebo Pill per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Postprandial Glucose Levels After Mixed Meal Test</title>
          <description>Glucose levels were measured in study participants while fasting and periodically over 3 hours after drinking a 200 kcal mixed meal test, before and after intervention (Sitagliptin or Placebo).</description>
          <population>All patients completed study in both arms.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Intervention Fasting Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="1.74"/>
                    <measurement group_id="O2" value="6.52" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention Fasting Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.44" spread="1.25"/>
                    <measurement group_id="O2" value="6.39" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Intervention 120 minute glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="1.91"/>
                    <measurement group_id="O2" value="7.01" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention 120 minute glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" spread="1.65"/>
                    <measurement group_id="O2" value="6.97" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Intervention Average Glucose during MMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.55" spread="1.95"/>
                    <measurement group_id="O2" value="8.12" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention Average Glucose during MMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.84" spread="1.47"/>
                    <measurement group_id="O2" value="7.86" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Power analysis. Based on the effect of DPP-4 inhibitors in non-operated subjects with type 2 diabetes, showing a significant decrease in 120’ post-prandial glucose by 1.67 mmol/L ± 0.98 mmol/L after a MMT, we estimated that a sample size of 16 subjects per group will show post-prandial glucose differences between placebo and sitagliptin group with α = 0.05 for a power &gt; 90%.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>P-value refers to paired t-test comparing pre-intervention and post-intervention timepoints in Sitagliptin group.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Area Under the Curve (AUC) Glucose Levels After Mixed Meal Test</title>
        <description>Glucose levels were measured in study participants while fasting and periodically over 3 hours after drinking a 200 kcal mixed meal test, before and after intervention (Sitagliptin or Placebo). AUC was measured by trapezoidal method.</description>
        <time_frame>Baseline and ~4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Phosphate</title>
            <description>100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Sitagliptin phosphate: 100 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 Placebo pill / day PO once a day for 4-5 weeks
Placebo: 1 Placebo Pill per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Area Under the Curve (AUC) Glucose Levels After Mixed Meal Test</title>
          <description>Glucose levels were measured in study participants while fasting and periodically over 3 hours after drinking a 200 kcal mixed meal test, before and after intervention (Sitagliptin or Placebo). AUC was measured by trapezoidal method.</description>
          <units>mmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Intervention Glucose AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.31" spread="1.92"/>
                    <measurement group_id="O2" value="7.96" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention Glucose AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.67" spread="1.59"/>
                    <measurement group_id="O2" value="7.75" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Sitagliptin vs Placebo on Satiety in Patients With Type 2 Diabetes After Gastric Bypass Surgery</title>
        <description>Satiety levels were measured in study participants while they were fasting and periodically over a three hour period after drinking a 200 kcal meal drink, before and after intervention via a Visual Analog Scale. Participants were asked to mark on a 0 to 150 millimeter scale their response to the following question: &quot;How full do you feel right now?&quot; with lower scores indicating &quot;not full at all&quot; and higher scores indicating &quot;extremely full.&quot;</description>
        <time_frame>Baseline and ~4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Phosphate</title>
            <description>100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Sitagliptin phosphate: 100 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 Placebo pill / day PO once a day for 4-5 weeks
Placebo: 1 Placebo Pill per day</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Sitagliptin vs Placebo on Satiety in Patients With Type 2 Diabetes After Gastric Bypass Surgery</title>
          <description>Satiety levels were measured in study participants while they were fasting and periodically over a three hour period after drinking a 200 kcal meal drink, before and after intervention via a Visual Analog Scale. Participants were asked to mark on a 0 to 150 millimeter scale their response to the following question: &quot;How full do you feel right now?&quot; with lower scores indicating &quot;not full at all&quot; and higher scores indicating &quot;extremely full.&quot;</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Intervention fasting satiety level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.94" spread="87.40"/>
                    <measurement group_id="O2" value="49.06" spread="39.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention fasting satiety level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.38" spread="22.03"/>
                    <measurement group_id="O2" value="58.50" spread="113.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Intervention 180 minute glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.81" spread="40.95"/>
                    <measurement group_id="O2" value="50.50" spread="59.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention 180 minute glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.69" spread="43.85"/>
                    <measurement group_id="O2" value="103.75" spread="198.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Side Effects In Relation to Sitagliptin</title>
        <description>Side effects to Sitagliptin or Placebo were measured in study participants via Sigstad score questionnaire, while fasting and periodically during a 3 hour period after drinking a 200 kcal meal drink, before and after intervention. The Sigstad scoring system is based on the participants report of the occurrence of 16 symptoms suggestive of the dumping syndrome. Each symptom is given a different score. For example, desire to sit down (+4), breathlessness (+3), dizziness (+2), nausea (+1), vomiting (-4) etc.The scale can range from -5 to 34. Scores greater than or equal to 7, after glucose intake, are considered diagnostic of dumping syndrome.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Phosphate</title>
            <description>100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Sitagliptin phosphate: 100 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 Placebo pill / day PO once a day for 4-5 weeks
Placebo: 1 Placebo Pill per day</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Side Effects In Relation to Sitagliptin</title>
          <description>Side effects to Sitagliptin or Placebo were measured in study participants via Sigstad score questionnaire, while fasting and periodically during a 3 hour period after drinking a 200 kcal meal drink, before and after intervention. The Sigstad scoring system is based on the participants report of the occurrence of 16 symptoms suggestive of the dumping syndrome. Each symptom is given a different score. For example, desire to sit down (+4), breathlessness (+3), dizziness (+2), nausea (+1), vomiting (-4) etc.The scale can range from -5 to 34. Scores greater than or equal to 7, after glucose intake, are considered diagnostic of dumping syndrome.</description>
          <units>units on Sigstad scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Intervention Average Sigstad Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="1.97"/>
                    <measurement group_id="O2" value="5.58" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention Average Sigstad Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="2.34"/>
                    <measurement group_id="O2" value="4.40" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active GLP-1</title>
        <description>Active GLP-1 (Fasting and during a Mixed Meal Test). The Change in Fasting Active GLP-1 refers to the change in fasting active GLP-1 from pre-intervention time point to post-intervention time point. The Change in Peak Active GLP-1 refers to the change in the peak active GLP-1 level from the pre-intervention time point to post-intervention time point.</description>
        <time_frame>Pre-Intervention and Post-Intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Phosphate</title>
            <description>100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Sitagliptin phosphate: 100 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 Placebo pill / day PO once a day for 4-5 weeks
Placebo: 1 Placebo Pill per day</description>
          </group>
        </group_list>
        <measure>
          <title>Active GLP-1</title>
          <description>Active GLP-1 (Fasting and during a Mixed Meal Test). The Change in Fasting Active GLP-1 refers to the change in fasting active GLP-1 from pre-intervention time point to post-intervention time point. The Change in Peak Active GLP-1 refers to the change in the peak active GLP-1 level from the pre-intervention time point to post-intervention time point.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Fasting Active GLP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="2.59"/>
                    <measurement group_id="O2" value="-0.22" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Peak Active GLP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.08" spread="15.46"/>
                    <measurement group_id="O2" value="2.97" spread="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 6 weeks (the time period a participant was involved in the study).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin Phosphate</title>
          <description>100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Sitagliptin phosphate: 100 mg/day orally</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1 Placebo pill / day PO once a day for 4-5 weeks
Placebo: 1 Placebo Pill per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study of short duration, designed as proof of concept. Absorption of sitagliptin may have been variable amongst subjects. The groups were small and the data cannot be extrapolated to a larger group of individuals with wide range of diabetes control.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Blandine Laferrere</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>212-851-5562</phone>
      <email>bbl14@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

